anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
GCBT was administered in addition to fluoxetine and consisted of 11 sessions for 8 weeks. It lasts 90 to 120 minutes, once or twice a week. At week 8, patients will be evaluated as "in remission" or "not in remission." "Patients who are not in remission" will be randomized to phase II treatment based on the patient's wishes.
PURPOSE:To provide the titled reusable capsule which detects the pH change in the environment when administered orally and reached the position of the predetermined intestine in the body, generates the restoring force in a spring, and applies the drug easily and directly to the small intestine or duodenal intestine by the restoring force. CONSTITUTION:The pH value in the body is detected by the electrodes 1, 3 generating the electrical potential corresponding to the pH level, using a pH detecting circuit 6 composed of e.g. the pH calculation circuit, the acidity detecting circuit, the neutral state detecting circuit and the discrimination circuit. When the capsule has reached the intestine in the body, the pH change from the acidic to neutral is detected by the above circuit, and the spring-triggering circuit 9 is energized. The circuit 9 contains, e.g. a heater. The spring 8 made of a shape memory alloy is heated by the heater to generate the restoring force, which slides the piston plate 10 to apply the drug 12 easily into the body. After the application of the drug, the capsule is discharged from the body through the small intestine and the large intestine, and is reused.
Obesity predisposes to metabolic dysfunction-associated fatty liver disease (MAFLD), cardiovascular disease, and type 2 diabetes. Accumulating evidence suggests a complex role of NLR family pyrin domain containing 3 (NLRP3) inflammasome function in multiple manifestations of the metabolic syndrome, with contradictory results. Its broad expression and pleiotropic functions during obesity led us to investigate the contribution of its expression in nonimmune versus immune cells to the development of obesity and MAFLD. Bone marrow chimerism was used to target NLRP3 deficiency to immune (ImmuneΔNlrp3) versus nonimmune (NonimmuneΔNlrp3) cells. Irradiated WT mice reconstituted with WT bone marrow served as controls. Mice were fed a 60% high-fat diet for 16 weeks. NonimmuneΔNlrp3 mice gained less weight and displayed reduced liver and epididymal white adipose tissue (epiWAT) mass. They also exhibited reduced adipocyte hypertrophy and increased epiWAT adipogenesis and lipolysis. Notable was the diminished hepatic steatosis in NonimmuneΔNlrp3 livers, which persisted even following equilibration of their body weight to that of the control. This was accompanied by a decline in liver triglycerides and in expression of transcriptional modules involved with lipid uptake, storage, and de novo lipogenesis. Thermogenic pathways in brown adipose tissue were comparable to control mice, but an elevation was observed in the genes encoding for lipid transporters and fatty acid oxidation. In contrast, deletion of NLRP3 in the immune cell compartment had limited effects on obesity and hepatic steatosis. Collectively, our results outline a prominent role for NLRP3 in nonimmune cells in facilitating MAFLD during constant energy surplus.
The invention particularly relates to a coating agent with the efficacy of antiphlogosis, itching relief, disinfection and sterilization and a preparation method thereof. The technical problem solved by the invention is to improve Binghuangfule ointment and increase compliance of patients. Particularly, the invention is realized by the following technical scheme that: Binghuangfule ointment is modified and prepared into a coating agent. The coating agent has the efficacy of antiphlogosis, itching relief, disinfection and sterilization. The weight ratios of raw material herbs of the coating agent are: 20-68 parts of rheum officinale, 1-40 parts of curcuma longa, 1-10 parts of scutellaria, 3-10 parts of licorice, 20-40 parts of sulfur, 0.1-6.5 parts of borneol, 0.1-4.5 parts of menthol. After the herbs are prepared into a coating agent, the using amount of the raw material of sulfur is reduced; the preparation process is simple and is easy to operate; the prepared coating agent has significant curative effect clinically, is superior to ointment, does not contaminate clothing, is light yellow or transparent, and has good compliance of patients.
The invention belongs to the field of piglet additives and particularly relates to a Chinese herbal medicine additive for piglets. The Chinese herbal medicine additive mainly comprises the following ingredients in parts by weight: 3-3.5 parts of Chinese yam, 3-3.5 parts of semen plantaginis, 2 parts of mangnolia officinalis, 1 part of liquorice, 1 part of costustoot, 1 part of green tangerine peel and 1 part of ephedra. The Chinese herbal medicine additive is prepared in such a way that multiple traditional Chinese medicines are ground together to form fine powder, and the fine powder is sieved and then uniformly mixed to be used; or a flavoring agent is added after the water extract of the multiple traditional Chinese medicines is added into an absorbing carrier to be dried. The obtained Chinese herbal medicine additive for the piglets has the functions of preventing and curing diarrhea, strengthening spleen, calming stomach and preventing respiratory diseases. In particular, the product in which the flavoring agent is added has a milky flavor, the bitter and astringent tastes of the Chinese herbal medicines can be masked, and the product has better palatability. Daily ingestion quantity can be more effectively increased, and the occurrence of diarrhea is obviously reduced.
<P>PROBLEM TO BE SOLVED: To provide a food material which can control the intake of saccharides as much as possible to contribute to health promotions such as the improvement in the reduction of serum cholesterol, the solution of obesity, and the prevention and improvement of menopausal disorders.  <P>SOLUTION: This food material is characterized by comprising soybean protein powder, gluten and Plantago asiatica seed coat powder, not containing saccharides, and containing the proteins as a main ingredient. The food material may further contain roasted wheat hull powder. It is preferable that the weight ratio of the soybean protein powder to the gluten is 8:2 to 5:5. It is preferable that the content of the Plantago asiatica seed coat powder is 0.25 to 1.0 wt.% based on the total amount of the Plantago asiatica seed coat powder and the gluten. The food material can be used to bake up in a cake or cookie-like state.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
PURPOSE OF REVIEW: Amyotrophic lateral sclerosis (ALS) has a strong genetic basis, but the genetic landscape of ALS appears to be complex. The purpose of this article is to review recent developments in the genetics of ALS.
RECENT FINDINGS: Large-scale genetic studies have uncovered more than 40 genes contributing to ALS susceptibility. Both rare variants with variable effect size and more common variants with small effect size have been identified. The most common ALS genes are C9orf72 , SOD1 , TARDBP and FUS . Some of the causative genes of ALS are shared with frontotemporal dementia, confirming the molecular link between both diseases. Access to diagnostic gene testing for ALS has to improve, as effective gene silencing therapies for some genetic subtypes of ALS are emerging, but there is no consensus about which genes to test for.
SUMMARY: Our knowledge about the genetic basis of ALS has improved and the first effective gene silencing therapies for specific genetic subtypes of ALS are underway. These therapeutic advances underline the need for better access to gene testing for people with ALS. Further research is needed to further map the genetic heterogeneity of ALS and to establish the best strategy for gene testing in a clinical setting.
1. This is a double blind placebo controlled trial in PD patients with NOH. The controlled portion consists of two visits (baseline and week 4) and a phone call (week 2). An open label extension will include a phone call (week 6) and a final visit (week 8). Subjects will undergo a baseline assessment including continuous tilt table (10 minutes supine / 30 minutes at 70o / 10 minute supine) measurements of arteriole BP. Assessment will be done in the "on" state 1-3 hours after last dose and 1-3 hours after last meal. During both supine and standing positions, subjects will undergo a quantified transcranial cerebral ultrasound of the middle cerebral artery. A secondary analysis of the posterior circulation (basilar artery) will also be done when technically possible. An experienced technician will use a Spencer ST-3 Transcranial Doppler and MHz frequency probes (Spencer Technologies, Redmond WA), with ability to display all data in real time with M-mode and spectral waveform, depth of sample volume, size of sample volume, peak systolic and end diastolic velocities, pulsatility index and frequency of transducer. Cerebral oxygenation will be assessed throughout the tilt table with an FORE-SIGHT ELITE Oximetry System (CASMED) with FORE-SIGHT ELITE large advanced sensor. Mean/Max/Min vales will be analyzed. The tilt table BP and HR monitor with autonomic function will be recorded with a Task Force monitor from CNsystem. Subjective assessments will be done prior to the tilt table and will include demographics, general medical history, UPDRS, and the orthostatic hypotension questionnaire, and some gait analysis. We will also query their subjective "light headedness" throughout the tilt table test to determine for objective correlates.
2. Subjects will be titrated with droxidopa or matching placebo over two weeks using current guidelines. The dose will be held constant for the final two weeks and taken on the day of the week 4 visit. After a safety and dose determination call at two weeks, subjects will return at 4 weeks for an identical evaluation, along with clinical global impressions of change.
3. All subjects will be allowed into a 4 week open label extension. They will start titration at 100 mg droxidopa TID but can titrate up daily if preferred. After a safety call (week 6) they will return for a final tilt table/ultrasound perfusion study/oximetry study and subjective questionnaires. The patients will be provided two additional weeks medication to ensure a safe transition to purchased droxidopa if desired.
BACKGROUND: In the era of combination therapy, there has been limited research on body composition. Specific body composition, such as sarcopenia, possesses the potential to serve as a predictive biomarker for toxic effects and clinical response in patients with urothelial carcinoma (UC) undergoing tislelizumab combined with gemcitabine and cisplatin (T + GC).
MATERIALS AND METHODS: A total of 112 UC patients who received T + GC were selected at the Affiliated Hospital of Xuzhou Medical University from April 2020 to January 2023. Baseline patient characteristics and detailed hematological parameters were collected using the electronic medical system and laboratory examinations. The computed tomography images of patients were analyzed to calculate psoas muscle mass index (PMI). We evaluated the association between sarcopenia (PMI < 4.5 cm2/m2 in men; PMI < 3.3 cm2/m2 in women) and both hematological toxicity and tumor response.
RESULTS: Overall, of the 112 patients (65.2% male, median age 56 years), 43 (38.4%) were defined as sarcopenia. Patients with sarcopenia were notably older (p = 0.037), more likely to have hypertension (p = 0.009), and had poorer ECOG-PS (p = 0.027). Patients with sarcopenia were more likely to develop leukopenia (OR 2.969, 95% CI 1.028-8.575, p = 0.044) after receiving at least two cycles of T + GC. However, these significant differences were not observed in thrombocytopenia and anemia. There were no significant differences in the tumor response and grade 3-4 hematological toxicity between patients with sarcopenia and those without sarcopenia.
CONCLUSIONS: Patients with sarcopenia were more likely to develop leukopenia after receiving T + GC. There were no notable alterations observed in relation to anemia or thrombocytopenia. No significant difference was found between the sarcopenia group and non-sarcopenia group in terms of tumor response and grade 3-4 hematological toxicity.
The efficacy of PLUVICTO was evaluated in VISION (NCT03511664), a randomized (2:1), multicenter, open-label trial that evaluated PLUVICTO plus BSoC (N = 551) or BSoC alone (N = 280) in men with progressive, PSMA-positive mCRPC. Randomization was stratified by baseline lactase dehydrogenase (LDH), presence of liver metastases, ECOG PS score and inclusion of an AR pathway inhibitor as part of BSoC at the time of randomization. All patients received a GnRH analog or had prior bilateral orchiectomy. Patients were required to have received at least one AR pathway inhibitor, and 1 or 2 prior taxane-based chemotherapy regimens. Eligible patients were required to have PSMA-positive mCRPC defined as having at least one tumor lesion with gallium Ga 68 gozetotide uptake greater than normal liver. Patients were excluded if any lesions exceeding size criteria in short axis [organs ≥ 1 cm, lymph nodes ≥ 2.5 cm, bones (soft tissue component) ≥ 1 cm] had uptake less than or equal to uptake in normal liver.

Patients received PLUVICTO 7.4 GBq (200 mCi) every 6 weeks for up to a total of 6 doses plus BSoC or BSoC alone. BSoC administered at the investigator’s discretion included ketoconazole; radiation therapy to localized prostate cancer targets; bone-targeted agents; androgen-reducing agents; AR pathway inhibitors. Patients continued treatment for up to 4-6 doses, or until disease progression or unacceptable toxicity. Patients with stable disease or partial response after 4 doses of PLUVICTO plus BSoC received up to 2 additional doses per investigator’s discretion.

The following patient demographics and baseline disease characteristics were balanced between the arms. The median age was 71 years (range, 40 to 94 years); 87% White; 7% Black or African American; 2.4% Asian; 92% had ECOG PS0-1; 8% had ECOG PS2. All patients had received at least one prior taxane-based chemotherapy regimen and 41% of patients received two. One prior AR pathway inhibitor had been administered to 51% of patients, 41% of patients received 2, and 8% of patients received 3 or more. During the treatment period, 53% of patients in the PLUVICTO plus BSoC arm and 68% of patients in the BSoC alone arm received at least one AR pathway inhibitor.

The major efficacy outcome measures were overall survival (OS) and radiographic progression-free survival (rPFS) by blinded independent central review (BICR) per Prostate Cancer Working Group 3 (PCWG3) criteria. An additional efficacy outcome measure included was overall response rate (ORR) by BICR per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

VISION demonstrated a statistically significant improvement in both major efficacy outcome measures of OS and rPFS by BICR with PLUVICTO plus BSoC compared to treatment with BSoC alone. Interpretation of the magnitude of the rPFS effect was limited due to a high degree of censoring from early drop out in the control arm.

Efficacy results for VISION are presented in Table 7 and Figure 1.

Figure 1. Kaplan-Meier Plot of Overall Survival in VISION
INTRODUCTION: Amyloidosis is a rare disease in which malformed proteins are deposited in tissues occurring mostly commonly in older age. These deposits can lead to severe organ dysfunction e.g. in the myocardium with great impact on prognosis. The Covid-19 pandemic has caused excess mortality worldwide since 2020. Risk factors for a severe course include pre-existing cardiac diseases like heart failure and advanced age. Therefore, vaccination against Sars-CoV2 viruses is highly recommended for patients with cardiac amyloidosis. However, since there are no specific data on mRNA vaccines in patients with cardiac amyloidosis, some patients have concerns about cardiac adverse events following immunization (AEFI), such as myocarditis.
PURPOSE: The purpose of the study is to assess the safety and efficacy of mRNA vaccines in patients with cardiac amyloidosis.
METHODS: Patients of the Amyloidosis Center Charité Berlin (ACCB) were assessed about the vaccination, its tolerability and clinical effectiveness. To date, we included 62 patients (54 men) with a median age of 82,5 years (range 37 to 92). 46 patients had wtATTR amyloidosis, ten patients had hATTR amyloidosis, and six patients had AL amyloidosis. The mean systolic left ventricular function was 51% (range 30 to 62) with a mean global strain of -11,5% (range -18,5 to -3,1). The mean NT-pro-BNP was 1145 ng/l (range 24 to 48297).
RESULTS: 59 patients were triple vaccinated and three patients so far are double vaccinated. Three of the patients were unvaccinated. 171 of the vaccine doses administered were mRNA vaccines and eight doses were a viral vector-vaccine. None of the patients reported severe side effects. Thirteen patients reported feeling of pressure and pain at the injection site after vaccination and four patients had fever of maximum two days, eight patients reported lower general condition of maximum five days. One patient reported malaise for 14 days after each vaccination, which resolved spontaneously. There was no clinical or laboratory evidence of suspected vaccine-induced myocarditis. Five patients reported of a COVID-19 breakthrough infection, all of which with a mild course of disease. None of the patients had symptoms of worsening heart failure in temporal relation to the vaccination. Most of the vaccinations (103) were performed at an official vaccination center, 59 were performed at a general practitioner.
CONCLUSION: In patients with cardiac amyloidosis, mRNA vaccines for COVID-19 are safe with respect to severe cardiac adverse events and show effective protection against clinically relevant SARS-CoV2 infection.
The invention relates to a traditional Chinese medicine for beautifying features and removing freckles, comprising the following components of traditional Chinese medicine with weight ratios as follows: angelica 1-1.5, medlar 1-1.3, safflower 1-1.4, peach kernel 1-1.33, astragalus root 1-1.5, mulberry 1-1.33, angelica dahurica 1-1.33 and chrysanthemum 1-1.4. The components of traditional Chinese medicine are made into patent medicine by a particular preparation method. Preferably, the traditional Chinese medicine can be made into an oral liquid, and the medicinal ingredients can be mixed with medicinal carriers or addition agents to be made into other medicament forms. Laboratory tests and detections indicate that 8mg ferulic acid and 0.7g crude polysaccharide exist in every 100ml of traditional Chinese medicine oral liquid. The oral liquid is especially suitable for people suffering from chloasma. Taking the oral liquid three times a day with 10ml each time for a long time can completely cure the chloasma in a safe and reliable way without any toxicity and side effect.
Participants will receive a single dose of TT-00420 tablet under fed conditions, followed by a single dose of TT-00420 tablet under fasted conditions, followed by a single dose of TT-00420 capsule under fasted conditions. There will be at least a 14-day wash-out period between each dose.
Propofol group: this group of patients receives propofol as the main anesthetic agent in addition to remifentanil infusion at the rate of 0.1\~0.3 mcg./g/min during one-lung anesthesia. Bispectral index will be maintained between 45 and 50. Arterial blood gases and pulmonary blood flow by using tansesphageal echocardiogrphy will be measured.
To prepare cephem derivatives of the formula I, a compound of the formula II is reacted with an acid of the formula Z-CH2-COOH, where the substituents have the meaning given in Patent Claim 1, or with a functional derivative, which is suitable for acylation, of such an acid. The resulting product is subsequently solvolysed and/or hydrogenolysed. Subsequent appropriate working up of the resulting compound of the formula I yields the readily cleavable esters and physiologically harmless salts thereof. The process is easy to carry out and the end products are obtained in good yield and at high purity. The end products which are obtained demonstrate antibacterial activity and can be used as drugs, in particular for controlling bacterial infections. <IMAGE>
Individuals will be asked to consume beef as their only source of protein and follow an individualized meal plan for 4 weeks. Thereafter, they will be instructed to continue beef consumption with any other foods desired for 4 weeks.
Day 1 of BRB will be determined based upon the anticipated surgery day. Subjects will be instructed to consume a total dose of 5 Gm/day (orally) by taking one BRB five times a day: one upon waking in the morning, one in the morning, one at noon, one in the evening, and one at bedtime. BRB should not be given during meals and drinking. The subject should avoid eating for about 30 minutes before and after taking a BRB.
INTRODUCTION: Canadian patients presenting to the emergency department (ED) typically undergo a triage process where they are assessed by a specially trained nurse and assigned a Canadian Triage and Acuity Scale (CTAS) score, indicating their level of acuity and urgency of assessment. We sought to assess the ability of patients to self-triage themselves through use of one of two of our proprietary self-triage tools, and how this would compare with the standard nurse-driven triage process.
METHODS: We enrolled a convenience sample of ambulatory ED patients aged 17 years or older who presented with chief complaints of chest pain, abdominal pain, breathing problems, or musculoskeletal pain. Participants completed one, or both, of an algorithm generated self-triage (AGST) survey, or visual acuity scale (VAS) based self-triage tool which subsequently generated a CTAS score. Our primary outcome was to assess the accuracy of these tools to the CTAS score generated through the nurse-driven triage process.
RESULTS: A total of 223 patients were included in our analysis. Of these, 32 (14.3%) presented with chest pain, 25 (11.2%) with shortness of breath, 75 (33.6%) with abdominal pain, and 91 (40.8%) with musculoskeletal pain. Of the total number of patients, 142 (47.2%) completed the AGST tool, 159 (52.8%) completed the VAS tool and 78 (25.9%) completed both tools. When compared to the nurse-driven triage standard, both the AGST and VAS tools had poor levels of agreement for each of the four presenting complaints.
CONCLUSIONS: Self-triage through use of an AGST or VAS tool is inaccurate compared to the established standard of nurse-driven triage. Although existing literature exists which suggests that self-triage tools developed for specific subsets of complaints may be feasible, our results would suggest that adopting the self-triage approach on a broader scale for all-comers to the ED does not appear to be a viable option to enhance the current triage process. Further study is required to show if self-triage can be used in the ED to optimize the triage process.
Five patients, of any sex and age, with bilateral COVID-19 pneumonia, severe SIRA with PaO2 / FiO2 less than 150, lymphopenia less than 800 total lymphocytes, CT with bilateral pneumonia, SOFA less than 11 and that has not improved in relation to the following parameters: a) persistent PaO2 / FiO2 less than 150; b) persistent fever, c) increase in D-dimer of at least 50% of the baseline and / or ferritin greater than 1000, after 48 h of hospital stay receiving the standard management measures used at that time in the Care Center, will be included in the study. This treatment will be administered after discussing it with the relatives that it is a procedure considered as rescue and will be carried out with informed consent.